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Background: We tested the feasibility of a simple method for assessment of prostate cancer (PCa) aggressiveness
using diffusion-weighted magnetic resonance imaging (MRI) to calculate apparent diffusion coefficient (ADC) ratios
between prostate cancer and healthy prostatic tissue.
Methods: The requirement for institutional review board approval was waived. A set of 20 standardized core
transperineal saturation biopsy specimens served as the reference standard for placement of regions of interest on
ADC maps in tumorous and normal prostatic tissue of 22 men with PCa (median Gleason score: 7; range, 6–9). A
total of 128 positive sectors were included for evaluation. Two diagnostic ratios were computed between tumor
ADCs and normal sector ADCs: the ADC peripheral ratio (the ratio between tumor ADC and normal peripheral zone
tissue, ADC-PR), and the ADC central ratio (the ratio between tumor ADC and normal central zone tissue, ADC-CR).
The performance of the two ratios in detecting high-risk tumor foci (Gleason 8 and 9) was assessed using the area
under the receiver operating characteristic curve (AUC).
Results: Both ADC ratios presented significantly lower values in high-risk tumors (0.48 ± 0.13 for ADC-CR and 0.40 ±
0.09 for ADC-PR) compared with low-risk tumors (0.66 ± 0.17 for ADC-CR and 0.54 ± 0.09 for ADC-PR) (p < 0.001) and
had better diagnostic performance (ADC-CR AUC = 0.77, sensitivity = 82.2%, specificity = 66.7% and ADC-PR
AUC = 0.90, sensitivity = 93.7%, specificity = 80%) than stand-alone tumor ADCs (AUC of 0.75, sensitivity = 72.7%,
specificity = 70.6%) for identifying high-risk lesions.
Conclusions: The ADC ratio as an intrapatient-normalized diagnostic tool may be better in detecting high-grade
lesions compared with analysis based on tumor ADCs alone, and may reduce the rate of biopsies.
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The assessment of local aggressiveness of prostate cancer
(PCa) is of key importance for appropriate management
of this disease. The increase in life expectancy of the
general population combined with efficient screening
methods will lead to an increase in the number of new
PCa cases [1]. These cases will tend to be more localized
and at an earlier stage. Over the last few years, new focal
methodologies have emerged for PCa treatment, such as* Correspondence: diana.feier@gmail.com
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reproduction in any medium, provided the orhigh-intensity focused ultrasound, cryotherapy, focal laser
ablation, intensity-modulated radiation therapy, radiofre-
quency ablation, and others. These relatively new thera-
peutic methods come as alternatives to existing treatment
modalities such as radical prostatectomy or radiotherapy
[2]. The diagnosis of PCa is based on physical (i.e., digital
rectal) examination, prostate specific antigen (PSA) levels,
and, when PSA levels are abnormal, blind biopsy. All of
these assessments are of low diagnostic accuracy [3-5].
Multiparametric magnetic resonance imaging (MRI) has
shown great potential, with significant improvement in
detection, localization, and characterization of PCa [6,7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Prostate segmentation showing ten posterior and six
anterior segments.
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treatment options, and for minimizing treatment-related
morbidity. Patients with tumors rated with a Gleason
score of 6 or greater represent an important target popula-
tion for PCa detection and effective therapy [8,9].
According to recent guidelines [10], multiparametric
MRI of the prostate includes three functional MR se-
quences: diffusion weighted imaging (DWI) [11], dynamic
contrast enhancement-MR [12], and MR spectroscopy
[13]. These sequences contribute to the PI-RADS scoring
system of prostate lesions [10], with DWI as the main con-
tributor. With a short acquisition time and high contrast
resolution between tumor and normal prostatic tissue
[14], DWI and apparent diffusion coefficient (ADC) map-
ping demonstrate an inverse and significant correlation
with the Gleason score [7,14]. Although ADC can estimate
tumor aggressiveness, there is still a large overlap between
ADCs of different tumors with the same Gleason score
[7]. The purpose of this study was to establish a simple
method for PCa assessment of tumor aggressiveness using
ADC ratios between prostate cancer and healthy prostatic
tissue.
Methods
We analyzed the images of 43 men who underwent
prostate MRI examinations with an endorectal coil in
our institution between February 2011 and August 2012.
Written informed consent had been obtained from pa-
tients prior to the MR examinations, as well as before all
interventions, such as prostatic biopsy. The requirement
to obtain written, informed consent for the retrospective
analysis of the data was waived. To be included in our
study, subjects needed to have biopsy-proven PCa from
a standard 20-core transperineal saturation biopsy. We
excluded five cases because of post-biopsy hemorrhage,
five cases because of motion artifacts, and 11 cases be-
cause of unavailable or negative biopsy specimens. Thus,
22 cases (median age: 64.5 years; range: 52–75 years)
were further selected in this retrospective single-center
study. All subjects had undergone MRI with an endorec-
tal coil including T2-weighted images (T2WI) and DWI
4–6 weeks after PCa confirmation by biopsy.
Saturation biopsy
Saturation biopsy was conducted under general anesthesia
in the supine position. The biopsy needle was guided with
transrectal ultrasound into the sectors (Figure 1) and 20
transperineal cores were obtained. Each biopsy core was
numbered, assigned to a sector, and sent for histopatho-
logical analysis.
Histopathological analysis
Biopsy specimens were fixed in formaldehyde, embed-
ded in paraffin, and stained with hematoxylin-eosin.The diagnosis was confirmed with immunohistochemistry
for basal cells (p63) and AMCAR expression (p504s). Re-
sults were reported as cancer with an assigned Gleason
score or as benign tissue.
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MRI was performed with a 1.5 T scanner (Symphony;
Siemens AG, Erlangen, Germany) using an eight-channel
phased array body coil combined with an endorectal coil
(MEDRAD, Inc., Warrendale PA, USA). After digital rectal
examination, the balloon of the endorectal coil was in-
flated with 60 mL of air. T2WI were obtained in axial,
coronal, and sagittal planes using turbo spin echo se-
quences and the entire prostate was investigated. DWI
was performed in the axial plane using echo-planar im-
aging (EPI) sequences at three b-values (0, 400, and
800 mm2/s) and restriction of diffusion was quantified
by ADC values. T2WI parameters and DWI parameters
are shown in Table 1.
Image interpretation
Image interpretation was done on a PACS station
(KODAK/Carestream Version 10.2; Carestream Health,
Rochester, NY, USA) by two radiologists with 5 years’
combined experience in uroradiology and prostate im-
aging and 3 years’ combined experience interpreting
DWI (L.A., C.C.). The readers were aware of the results
of biopsy and clinical data. PCa-positive biopsy cores
were assigned to a 16-region standardized prostate report-
ing scheme including ten posterior and six anterior glan-
dular sectors (Figure 1) as recommended by Dickinson
et al. [15]. ADC maps were generated from the DWI
sequences, and regions of interest (ROIs) were placed
according to biopsy results and the prostate reporting
scheme. Lesions with low signal intensity compared
with surrounding tissue on ADC were considered ma-
lignant. ROIs were drawn to occupy approximately 75%
of the lesion in a given segment to be sure that normal
tissue outside lesion margins would not be included.
ROIs were drawn also in the tumor-free sectors, with aTable 1 MRI parameters’ description
T2W-MRI DW-MRI
Sequence Fast spin echo Spin echo EPI
TR (ms) 5500 3200
TE (ms) 104 90
Flip angle 150°
FOV (mm2) 180 × 180 300 × 300
Matrix 256 × 256 128 × 128
Voxel size (mm3) 0.8 × 0.8 × 3 2.3 × 2.3 × 4
Slice thickness (mm) 3 4
Gap (mm) 0.3 0.3
Spectral suppression No Yes
b-values - 0/400/800
NEX 1 2
TA (min:sec) 4:09 2:40standard ROI size of 0.8 cm2. The mean signal intensity
was measured automatically by the PACS system. ADC
ratios were calculated by dividing tumoral ADCs by
tumor-free ADCs from the peripheral and the central
zones of the gland (Figure 2A and B). The highest ADCs
of normal sectors were taken as reference values. T2WI
and T1-weighted images (T1WI) were assessed for
post-biopsy hemorrhage.
Statistical analysis
The analysis was performed per patient and per tumor
unit accordingly. Categorical variables were presented
as numbers and percentages. Continuous variables wereFigure 2 Placement of regions of interest (ROI) for (A)
peripheral gland tumor (B) central gland tumor. A. Placement
of regions of interest (ROI) for signal intensity measurements of
Gleason 8 (4 + 4) peripheral tumor (white ROI = 0.78 × 10−3 mm2/s)
and normal peripheral zone (black ROI = 1.9 × 10−3 mm2/s). The
ADC-PR (white ROI/black ROI) is 0.41, which indicates a high-grade
tumor. B. The white ROI is placed in the central gland (CG) portion
of a Gleason 9 (4 + 5) lesion (0.82 × 10−3 mm2/s) while the black ROI
is located in tumor-free CG tissue (1.87 × 10−3 mm2/s) The ADC-CR
(white ROI/black ROI) is 0.43, which indicates a high-grade prostate
tumor.
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dian and range, as appropriate. We used a linear multi-
level model, so no linearity or normality assumptions
were made. The discriminative capability of each ADC
ratio was determined by calculating the area under the
receiver operating characteristic curve (AUC). Optimal
cut-off values were chosen to maximize the Youden index,
and sensitivity (%) and specificity (%) were computed from
the same data, without further adjustments. Discrim-
inative capability was examined per tumor unit and not
per patient, because of the low number of available pa-
tients. Comparisons were performed among different
ADCs using the Student’s t-test for continuous variables
and p < 0.05 was considered statistically significant. The
statistical analysis was performed using commercially
available software (MedCalc version 12.4.0; MedCalc
Software, Mariakerke, Belgium).
Results
Median PSA serum levels were 15.5 ng/mL (range, 6.8–
100 ng/mL) and median prostate volume was 44 mL
(range, 31–67 mL). On saturation biopsy, cancer was de-
tected in 157 of the 440 cores (36%). After assigning the
cancer-positive cores to the 16-region standardized pros-
tate reporting scheme, 128 out of 352 regions were cancer
positive (36%). The median Gleason score was 7 (range:
6–9). Gleason score 6 tumors were detected in 12 regions,
Gleason score 7 tumors were detected in 38 regions,
Gleason score 8 tumors were detected in 31 regions, and
Gleason score 9 tumors were detected in 46 regions. From
the positive tumor sectors, 86 (67%) were peripherally
located, while 42 (33%) were centrally located.
ADC findings
Results of mean prostatic tumor ADC for lower-grade
cores (Gleason 6 and 7) and higher-grade cores (Gleason
8 and 9) were significantly different (p < 0.001), as were
the ADC-PR and ADC-CR (p < 0.0001), as presented in
Table 2.Table 2 ADC and ADC-R characteristics of 128 prostatic secto
and high-risk group (Gleason 8 and 9)
Biopsy specimen characteristics Gleason 6 and 7 (n
*Number of patients 14 (64%)
Age (years) 66 (56–76)
PSA (ng/mL) 10.74 (3.5-25)
ADC (mm2/sec) 0.88 × 10−3 ± 0.13
Normal central zone ADC (mm2/sec) 1.38 × 10−3 ± 0.24
Normal peripheral zone ADC (mm2/sec) 1.64 × 10−3 ± 0.19
ADC-CR 0.66 ± 0.17
ADC-PR 0.54 ± 0.09
Note: Data are presented as mean and standard deviation or median and range, ex
ADC-CR: ratio between tumor ADCs and healthy central gland tissue ADCs. ADC-PRFor a cut-off level ≤ 0.82 ± 0.32 × 10−3 mm2/s, the
tumor ADCs for Gleason 8 and 9 positive sectors
showed a sensitivity and specificity of 72.7 and 70.6%,
while the AUC was 0.75. Using a cut-off value ≤ 0.57,
the ADC-CR showed more promising results with sen-
sitivity = 82.2%, specificity = 66.7%, and AUC of 0.77
(Table 3). The best diagnostic performance was obtained
for ADC-PR, with an AUC of 0.84, when applying a
cut-off value ≤ 0.5.
When analyzing the performance for ADC-PR in detect-
ing tumors with a high Gleason score (8 or 9) in relation
to the lesion location, the ratio had robust accuracy in de-
tecting central zone tumors (AUC = 0.81) and an excellent
discriminatory ability to detect tumors located in the
peripheral zone (AUC = 0.90) (Figure 3). The results are
summarized in Table 4.
Discussion
Our study shows promising results in the assessment of
PCa aggressiveness using tumor-to-normal ADC ratios.
In this study, both central and peripheral ADC ratios
demonstrated a better sensitivity, specificity, and AUC
than the interpretation of ADCs alone, with the most
promising results obtained for the ratios computed using
normal ADCs measured in the periphery of the gland. It
is not yet possible to find a cut-off value to delineate
malignant tissue from benign because of the overlap of
ADCs of PCa and those of normal prostatic tissue; even
Gleason 9 tumors showed ADCs up to 1.27 × 10−3 mm2/s.
This finding is well known; Litjens et al. concluded in
their study that tumor ADCs should not be considered
absolute because of the influence of “background” vari-
ation of normal peripheral zone (PZ) tissue composition
[16]. This statement is supported by the results of our
study, in which we were able to demonstrate better
AUC for ADC ratios in comparison with tumor ADCs
alone. In our study, the ADCs of the PCa-positive bi-
opsy cores showed statistically significant differences
from the biopsy cores of normal PZ and central glandrs for low- and intermediate-risk group (Gleason 6 and 7)




0.73 × 10−3 ± 0.17 <0.001
1.59 × 10−3 ± 0.22 <0.001
1.90 × 10−3 ± 0.35 <0.001
0.48 ± 0.13 <0.001
0.41 ± 0.09 <0.001
cept where indicated. *: Data are presented as number and percentages.
: ratio between tumor ADCs and healthy peripheral zone tissue ADCs.
Table 3 DWI cut-off values and performance values of
tumor ADC, ADC-CR, and ADC-PR in predicting Gleason
8 and 9
Tumor ADC ADC-CR ADC-PR
Cut-off ≤ 0.82 ≤ 0.57 ≤ 0.5
Sensitivity 72.7 82.2 88.9
Specificity 70.6 66.7 64.7
AUROC 0.75 0.77 0.84
p value < 0.001 < 0.001 < 0.001
Note: AUC: area under the receiver operating characteristic curve. ADC-CR: ratio
between tumor ADCs and healthy central gland tissue ADCs. ADC-PR: ratio
between tumor ADCs and healthy peripheral zone tissue ADCs.
Table 4 The cut-off values and diagnostic performance of
ADC-Peripheral Ratio in predicting Gleason 8 and 9
stages, according to tumor location
Central zone tumors Peripheral zone tumors




p value < 0.001 < 0.001
Note: AUC: area under the receiver operating characteristic curve.
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published [17-19]. The mean ADC for positive PCa cores
in our group (0.79 ± 0.18 × 10−3 mm2/s) was slightly higher
than the one reported by Woodfield et al. [14] (0.737 ±
0.154 × 10−3 mm2/s, range, 0.108–1.263 × 10−3 ) but lower
than results published recently by Yamamura et al. [18]
(0.96 ± 0.24 × 10−3 mm2/s), Rinaldi et al. [19] (0.99 ±
0.15 × 10−3 mm2/s) and Nagayama et al. [20] (1.07 ±
0.35 × 10−3 mm2/s) (p > 0.5). The lower ADCs for positive
cores in our study group were probably because of the
high number of Gleason score 8 and 9 biopsy-proven
sectors, which exceeded 60% of all PCa positive biop-
sies. This large number of biopsy-proven, high-grade
PCa is likely the consequence of larger tumors in this
group of patients and a higher percentage of positiveFigure 3 Comparison of receiver operating characteristic curves
for tumor ADC, ADC-CR, and ADC-PR for cases with Gleason
scores 8 and 9.biopsy cores (for example, all 20 biopsy cores were
tumor-positive in two patients).
Healthy PZ prostatic tissue is rich in tubular structures,
allowing water molecules to move easily. As a conse-
quence, the ADCs of healthy PZ are high. Published ADC
mean values for PZ have been 1.65 ± 0.21 × 10−3 mm2/s
and 1.73 ± 0.27 × 10−3 mm2/s [15,18]. Our study of the
normal PZ shows similar results, with a mean ADC of
1.71 ± 0.32 × 10−3 mm2/s. Normal CG structure is com-
posed of two different tissues, a glandular component with
high signal intensity on T2WI and a stromal component
with low signal intensity on T2WI, which can mimic
PCa. The ADCs of normal CG should be lower than
normal values from the PZ because of benign stromal
hyperplasia changes taking place in the central gland.
Oto et al. showed that there is a significant difference
between ADCs of hyperplasic stromal nodules (1.27 ±
0.21 × 10−3 mm2/s) and hyperplastic glandular nodules
(1.73 ± 0.28 × 10−3 mm2/s) [21]. Our measurements
were done on the entire CG including both macro-
scopically stromal and glandular areas and the mean
ADC was 1.44 ± 0.22 × 10−3 mm2/s, which is lower
than the PZ ADC and close to the results published by
Oto et al. [22].
When comparing the Gleason scores, the ADC values
in subjects with Gleason 6 and 7 were significantly lower
than those with Gleason 8 and 9. As an additional obser-
vation, patients with Gleason 8 and 9 were significantly
younger (p < 0.0001). We hypothesize that the ADC dif-
ferences arise from natural variations in prostate physi-
ology in younger patients, owing to less significant fibrotic
and atrophic changes of prostate glandular structure that
would tend to decrease the ADC measurements [17].
In the last several years, many authors have investigated
the correlation between ADC and Gleason score. Wood-
field et al. [14] demonstrated a statistically significant dif-
ference between ADCs of low-grade tumors (Gleason 6)
and intermediate-grade tumors (Gleason 7) and between
low-grade tumors and high-grade tumors (Gleason 8
and 9). Verma et al. [7], in a large study of 197 prostate
tumors, concluded that ADCs negatively correlated
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capacity of ADC mapping to predict the presence of
high-grade tumors in patients with Gleason 6 (3 + 3)
findings on biopsy. Although there are promising re-
sults with DWI, there are still discrepancies between
ADCs of PCa and the final Gleason score in the many
papers published. The differences among ADCs can be
explained by physiologic factors such as age and tumor
size and by technical factors (e.g., acquisition parameters,
software, and the use of endorectal coils). The results of
our study are very encouraging; we demonstrated that
there is a statistically significant difference between ADCs
of low- and intermediate-grade tumors compared with
high-grade tumors. Our results are consistent with those
reported by Woodfield et al. [14].
PCa is a major health problem. The diagnostic meth-
odology remains practically the same, with ultrasound-
guided systematic biopsy as the main diagnostic modality.
Systematic biopsy has important limitations; it can miss
up to 35% of cancers [23], and the Gleason score result-
ing from systematic biopsy has to be upstaged in up to
50% of the patients after radical prostatectomy [24]. In
addition, Nam et al. concluded in their extensive study
that complications after TRUS-guided biopsy have in-
creased dramatically in the last 10 years [25]. With,
new less-invasive focal therapy techniques and the ac-
tive surveillance approach (which is based only on bi-
opsy results), it is of great importance to improve PCa
detection, characterization, and staging while reducing
biopsy-related morbidity as much as possible.
The results of this study show the potential of ADC
mapping in estimating the aggressiveness of PCa. By
analyzing the ADC ratios when applying DWI sequences
in PCa imaging, we can detect high-grade tumors more
accurately than when carrying out analysis based on
ADC alone. From our point of view, ADC mapping has
the potential to guide the biopsy needle into the most
aggressive region of a malignant lesion, resulting in fewer
and more accurate biopsies, better staging, and more in-
formation to select appropriate treatment options.
We have to state several limitations: (1) We used a
systematic biopsy as the reference standard, even though
it may miss a substantial percentage of prostate cancers.
However, it is the method of choice for cancer detection.
(2) Our study population was relatively small. Patients
with Gleason 8 and 9 scores tend to be younger than
patients with Gleason 6 and 7 scores, so the cases could
not be age-matched. (3) We do not have data on intraob-
server and interobserver variability. (4) Prostate biopsy
was performed prior to MRI examination, which might
have influenced the ADC measurements. The presence of
microscopic hemorrhage undetectable on standard MRI
sequences might have altered the ADC values and under-
estimated the diagnostic value of ADC ratios.Conclusions
The ADC tumor-to-normal ratio may be more predictive
of tumor grade than analysis based on ADCs alone.
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